Tevogen Bio has expanded its partnership with Microsoft, aiming to further its AI-centred collaboration and advance its predictive precision T-cell targeting technology, PredicTcell.

The strategic move is set to leverage Microsoft's cloud capabilities, AI and health and life sciences expertise to speed up the detection of target and pre-clinical processes, enhancing Tevogen’s immunotherapy pipeline.

Microsoft's advanced AI tools and the Azure cloud platform will be integrated by Tevogen.AI, the AI division of Tevogen Bio, into two key objectives.

The aim is the rapid expansion of the ExacTcell Technology pre-clinical pipeline, based on the trial outcomes of TVGN 489.

By utilising machine learning for critical simulations, the company expects to accelerate the discovery of new targets through the analysis of extensive genomic datasets with enhanced speed and precision.

The partnership is set to develop algorithms for decoding interactions between human leukocyte antigens and T-cells.

This is anticipated to advance the company's understanding of immune responses and pave the way for new therapeutic opportunities.

Tevogen Bio chief information officer and Tevogen.AI head Mittul Mehta stated: “As we expand our AI efforts, this broader relationship with Microsoft represents a key milestone in our ongoing journey to revolutionise immunotherapy.

“Through deeper collaboration with Microsoft domain experts, we will further harness the power of AI to bring more precise and personalised treatments to patients at an accelerated pace.”

Tevogen Bio is also exploring human papillomavirus (HPV) treatments through the Microsoft Azure cloud platform and AI tools.

A protein dataset from the HPV genome was curated by the company and is in the process of detecting cytotoxic T-cell (CTL) targets for a trial of Tevogen’s first oncology product candidate, TVGN 920.

With its ExacTcell technology, which trains CTLs to identify certain targets and then expands them, the company is poised to deliver an HPV-specific CTL treatment.

This expanded relationship with Microsoft builds on a previous partnership established in November 2024 to advance the development of an HPV-specific CTL treatment.

"Tevogen Bio and Microsoft expand AI collaboration to PredicTcell tech" was originally created and published by Pharmaceutical Technology , a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.